EBMT更新:血液系统恶性肿瘤干细胞移植后GVHD的预防与管理共识建议
欧洲血液与骨髓移植学会(EBMT)基于2014年后发表的研究证据,通过文献检索、专家讨论和德尔菲法更新了异基因造血干细胞移植后移植物抗宿主病(GVHD)的预防与管理建议,共形成38条声明,其中29条达100%共识、9条达95%共识。关键更新包括更广泛使用兔抗T细胞球蛋白、降低2级急性GVHD的激素剂量、支气管闭塞综合征使用特定药物组合,以及难治性GVHD的新治疗选择。
要点
- 更广泛使用兔抗T细胞球蛋白预防GVHD
- 2级急性GVHD(孤立皮肤或上消化道表现)采用较低激素剂量
- 支气管闭塞综合征使用氟替卡松、阿奇霉素和孟鲁司特
核心结论
- EBMT更新了GVHD预防与管理共识建议,共38条声明,29条达100%共识、9条达95%共识。
- 关键更新包括更广泛使用兔抗T细胞球蛋白、降低2级急性GVHD激素剂量、支气管闭塞综合征特定药物组合及难治性GVHD新治疗选择。
- 建议将这些推荐作为干细胞移植期间GVHD常规管理的基础。
研究设计与样本
- 指南类:EBMT移植并发症工作组5名成员基于证据和2014年建议创建38条声明。
- 招募20名GVHD管理专家组成专家小组,采用两轮电子邮件德尔菲法达成共识。
- 证据检索分三步:广泛扫描已发表试验、荟萃分析和系统综述;针对特定问题增加专家意见;针对争议或快速更新问题细化检索。
- 采用改良国家综合癌症网络(NCCN)证据与共识分类标准对声明进行分级。
主要发现
- 29条推荐达100%共识,9条推荐达95%共识。
- 关键更新包括更广泛使用兔抗T细胞球蛋白。
- 2级急性GVHD伴孤立皮肤或上消化道表现时采用较低激素剂量。
- 支气管闭塞综合征应使用氟替卡松、阿奇霉素和孟鲁司特。
- 难治性急性和慢性GVHD增加了新的治疗选择。
关键数值与推荐
- 38条声明涵盖GVHD预防、药物管理以及急性和慢性GVHD治疗。
- 29条推荐达100%共识,9条推荐达95%共识。
临床怎么用
- 推荐用于成人血液系统恶性肿瘤HLA相合同胞或无关供者移植后GVHD的常规管理。
- 临床可参照更广泛使用兔抗T细胞球蛋白、降低特定2级急性GVHD激素剂量等更新要点。
- 支气管闭塞综合征可使用氟替卡松、阿奇霉素和孟鲁司特。
- 难治性急性和慢性GVHD可考虑新增治疗选择。
- 半相合移植和儿童患者的管理无正式推荐,需个体化决策。
局限性
- 证据来自设计良好的大规模临床研究数量较少,全球GVHD预防和治疗存在较大差异。
- 半相合移植和儿童患者的GVHD预防与管理未提供正式推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Graft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity after allogeneic stem-cell transplantation. Because of the small number of results from well designed, large-scale, clinical studies there is considerable variability in the prevention and treatment of GVHD worldwide. In 2014, to standardise treatment approaches the European Society of Blood and Marrow Transplantation published recommendations on the management of GVHD in the setting of HLA-identical sibling or unrelated donor transplantation in adult patients with haematological malignancies. Here we update these recommendations including the results of study published after 2014. Evidence was searched in three steps: first, a widespread scan of published trials, meta-analyses, and systematic reviews; second, expert opinion was added for specific issues following several rounds of debate; and third, a refined search to target debated or rapidly updating issues. On the basis of this evidence and the 2014 recommendations, five members of the EBMT Transplant Complications Working Party created 38 statements on GVHD prophylaxis, drug management, and treatment of acute and chronic GVHD. Subsequently, they created the EBMT GVHD management recommendation expert panel by recruiting 20 experts with expertise in GVHD management. An email-based, two-round Delphi panel approach was used to manage the consensus. Modified National Comprehensive Cancer Network categories for evidence and consensus were applied to the approved statements. We reached 100% consensus for 29 recommendations and 95% consensus for nine recommendations. Key updates to these recommendations include a broader use of rabbit anti-T-cell globulin; lower steroid doses for the management of grade 2 acute GVHD with isolated skin or upper gastrointestinal tract manifestations; fluticasone, azithromycin, and montelukast should be used for bronchiolitis obliterans syndrome; and the addition of newer treatment options for resteroid-refractory acute and chronic GVHD. In addition, we discuss specific aspects of GVHD prophylaxis and management in the setting of haploidentical transplantation and in paediatric patients, but no formal recommendations on those procedures have been provided in this Review. The European Society of Blood and Marrow Transplantation proposes to use these recommendations as a basis for the routine management of GVHD during stem-cell transplantation.
引用
- Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020. PMID: 32004485. doi:10.1016/S2352-3026(19)30256-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。